Loading…

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent i...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2020-02, Vol.25 (2), p.140-149
Main Authors: Chan, Karmela Kim, Magro, Cynthia, Shoushtari, Alexander, Rudin, Charles, Rotemberg, Veronica, Rossi, Anthony, Lezcano, Cecilia, Carrino, John, Fernandez, David, Postow, Michael A, Apollo, Arlyn, Lacouture, Mario E, Bass, Anne R
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 149
container_issue 2
container_start_page 140
container_title The oncologist (Dayton, Ohio)
container_volume 25
creator Chan, Karmela Kim
Magro, Cynthia
Shoushtari, Alexander
Rudin, Charles
Rotemberg, Veronica
Rossi, Anthony
Lezcano, Cecilia
Carrino, John
Fernandez, David
Postow, Michael A
Apollo, Arlyn
Lacouture, Mario E
Bass, Anne R
description Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. The condition is rare, yet at our institutions we have seen four cases in the past 3 years. We describe our 4 cases and review 11 other cases reported in the literature. We present four cases of eosinophilic fasciitis following treatment with programmed cell death protein 1 or programmed cell death-ligand 1 blockade. All patients had extremity involvement with characteristic skin changes ranging from peripheral edema to induration, tightening, and joint limitation. The patients had varying degrees of peripheral eosinophilia. In two of our patients, the diagnosis was made by full-thickness skin biopsy showing lymphocytic infiltration of the subcutaneous fascia, with CD4+ T cells predominating in one case and CD8+ T cells in the other. In the other two cases, the diagnosis was made on the basis of characteristic imaging findings in the context of clinical features consistent with the diagnosis. All four patients were treated with glucocorticoids with varying degrees of success; immunotherapy had to be discontinued in all four. Patients with advanced melanoma who experienced this adverse effect had either a partial response or a complete response to therapy. Eosinophilic fasciitis can occur as a result of checkpoint inhibitor therapy. Although a tissue diagnosis is the gold standard, imaging studies may facilitate the diagnosis in the presence of consistent clinical features, but a degree of suspicion is key to recognizing the condition early. Therapy requires a collaborative approach by oncology, rheumatology, and dermatology; physical therapy is an important adjunct in treatment. For advanced melanoma, it may be a good prognostic indicator. It is important for clinicians to recognize that eosinophilic fasciitis is a potential immune-related adverse event (irAE) as a consequence of immune checkpoint inhibitor therapy. The presentation is quite stereotypical; the diagnosis can be made by imaging in the absence of a full-thickness skin biopsy. Early intervention is important to limit morbidity. This irAE may be a good prognostic sign among patients with melanoma.
doi_str_mv 10.1634/theoncologist.2019-0508
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7011633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32043775</sourcerecordid><originalsourceid>FETCH-LOGICAL-p163t-ad60bdd65494e2bbda494b92e9dc01dbb36883c47baf47bc790fc8db2b887fe43</originalsourceid><addsrcrecordid>eNpVkN1Kw0AQhRdRbK2-gu4LpG6ySTbxQpDQaiEgSAXvwv6lGU13Q3bb0rd3wR_0ZubAnPmYMwjdxGQe5zS99Z22RtrebsD5eULiMiIZKU7QNM7SMkpL8nYaNCloxOKsnKAL594JCZIm52hCE5JSxrIpUgvrwNihgx4kXnInATw4vLR9bw9gNrjqtPwYLBiPV6YDAd6OeN3pkQ_Hu-DbjbjiTjvMjcIcv-g96AO2La7BB5PfjfoSnbW8d_rqu8_Q63Kxrp6i-vlxVT3U0RBC-YirnAil8pAg1YkQigchykSXSpJYCUHzoqAyZYK3oUhWklYWSiSiKFirUzpD91_cYSe2Wklt_Mj7Zhhhy8djYzk0_ycGumZj9w0jcbiABsD1X8Dv5s-_6CdnYXTh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature</title><source>Open Access: PubMed Central</source><source>Oxford University Press Open Access</source><source>EZB Electronic Journals Library</source><creator>Chan, Karmela Kim ; Magro, Cynthia ; Shoushtari, Alexander ; Rudin, Charles ; Rotemberg, Veronica ; Rossi, Anthony ; Lezcano, Cecilia ; Carrino, John ; Fernandez, David ; Postow, Michael A ; Apollo, Arlyn ; Lacouture, Mario E ; Bass, Anne R</creator><creatorcontrib>Chan, Karmela Kim ; Magro, Cynthia ; Shoushtari, Alexander ; Rudin, Charles ; Rotemberg, Veronica ; Rossi, Anthony ; Lezcano, Cecilia ; Carrino, John ; Fernandez, David ; Postow, Michael A ; Apollo, Arlyn ; Lacouture, Mario E ; Bass, Anne R</creatorcontrib><description>Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. The condition is rare, yet at our institutions we have seen four cases in the past 3 years. We describe our 4 cases and review 11 other cases reported in the literature. We present four cases of eosinophilic fasciitis following treatment with programmed cell death protein 1 or programmed cell death-ligand 1 blockade. All patients had extremity involvement with characteristic skin changes ranging from peripheral edema to induration, tightening, and joint limitation. The patients had varying degrees of peripheral eosinophilia. In two of our patients, the diagnosis was made by full-thickness skin biopsy showing lymphocytic infiltration of the subcutaneous fascia, with CD4+ T cells predominating in one case and CD8+ T cells in the other. In the other two cases, the diagnosis was made on the basis of characteristic imaging findings in the context of clinical features consistent with the diagnosis. All four patients were treated with glucocorticoids with varying degrees of success; immunotherapy had to be discontinued in all four. Patients with advanced melanoma who experienced this adverse effect had either a partial response or a complete response to therapy. Eosinophilic fasciitis can occur as a result of checkpoint inhibitor therapy. Although a tissue diagnosis is the gold standard, imaging studies may facilitate the diagnosis in the presence of consistent clinical features, but a degree of suspicion is key to recognizing the condition early. Therapy requires a collaborative approach by oncology, rheumatology, and dermatology; physical therapy is an important adjunct in treatment. For advanced melanoma, it may be a good prognostic indicator. It is important for clinicians to recognize that eosinophilic fasciitis is a potential immune-related adverse event (irAE) as a consequence of immune checkpoint inhibitor therapy. The presentation is quite stereotypical; the diagnosis can be made by imaging in the absence of a full-thickness skin biopsy. Early intervention is important to limit morbidity. This irAE may be a good prognostic sign among patients with melanoma.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2019-0508</identifier><identifier>PMID: 32043775</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Immuno‐Oncology</subject><ispartof>The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.140-149</ispartof><rights>AlphaMed Press 2019.</rights><rights>AlphaMed Press 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-8619-8588 ; 0000-0002-8065-4412 ; 0000-0001-5204-3465 ; 0000-0002-3367-7961 ; 0000-0003-0639-2677 ; 0000-0002-3225-8351 ; 0000-0003-3472-2469 ; 0000-0002-4818-3710</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011633/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011633/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32043775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, Karmela Kim</creatorcontrib><creatorcontrib>Magro, Cynthia</creatorcontrib><creatorcontrib>Shoushtari, Alexander</creatorcontrib><creatorcontrib>Rudin, Charles</creatorcontrib><creatorcontrib>Rotemberg, Veronica</creatorcontrib><creatorcontrib>Rossi, Anthony</creatorcontrib><creatorcontrib>Lezcano, Cecilia</creatorcontrib><creatorcontrib>Carrino, John</creatorcontrib><creatorcontrib>Fernandez, David</creatorcontrib><creatorcontrib>Postow, Michael A</creatorcontrib><creatorcontrib>Apollo, Arlyn</creatorcontrib><creatorcontrib>Lacouture, Mario E</creatorcontrib><creatorcontrib>Bass, Anne R</creatorcontrib><title>Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. The condition is rare, yet at our institutions we have seen four cases in the past 3 years. We describe our 4 cases and review 11 other cases reported in the literature. We present four cases of eosinophilic fasciitis following treatment with programmed cell death protein 1 or programmed cell death-ligand 1 blockade. All patients had extremity involvement with characteristic skin changes ranging from peripheral edema to induration, tightening, and joint limitation. The patients had varying degrees of peripheral eosinophilia. In two of our patients, the diagnosis was made by full-thickness skin biopsy showing lymphocytic infiltration of the subcutaneous fascia, with CD4+ T cells predominating in one case and CD8+ T cells in the other. In the other two cases, the diagnosis was made on the basis of characteristic imaging findings in the context of clinical features consistent with the diagnosis. All four patients were treated with glucocorticoids with varying degrees of success; immunotherapy had to be discontinued in all four. Patients with advanced melanoma who experienced this adverse effect had either a partial response or a complete response to therapy. Eosinophilic fasciitis can occur as a result of checkpoint inhibitor therapy. Although a tissue diagnosis is the gold standard, imaging studies may facilitate the diagnosis in the presence of consistent clinical features, but a degree of suspicion is key to recognizing the condition early. Therapy requires a collaborative approach by oncology, rheumatology, and dermatology; physical therapy is an important adjunct in treatment. For advanced melanoma, it may be a good prognostic indicator. It is important for clinicians to recognize that eosinophilic fasciitis is a potential immune-related adverse event (irAE) as a consequence of immune checkpoint inhibitor therapy. The presentation is quite stereotypical; the diagnosis can be made by imaging in the absence of a full-thickness skin biopsy. Early intervention is important to limit morbidity. This irAE may be a good prognostic sign among patients with melanoma.</description><subject>Immuno‐Oncology</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkN1Kw0AQhRdRbK2-gu4LpG6ySTbxQpDQaiEgSAXvwv6lGU13Q3bb0rd3wR_0ZubAnPmYMwjdxGQe5zS99Z22RtrebsD5eULiMiIZKU7QNM7SMkpL8nYaNCloxOKsnKAL594JCZIm52hCE5JSxrIpUgvrwNihgx4kXnInATw4vLR9bw9gNrjqtPwYLBiPV6YDAd6OeN3pkQ_Hu-DbjbjiTjvMjcIcv-g96AO2La7BB5PfjfoSnbW8d_rqu8_Q63Kxrp6i-vlxVT3U0RBC-YirnAil8pAg1YkQigchykSXSpJYCUHzoqAyZYK3oUhWklYWSiSiKFirUzpD91_cYSe2Wklt_Mj7Zhhhy8djYzk0_ycGumZj9w0jcbiABsD1X8Dv5s-_6CdnYXTh</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Chan, Karmela Kim</creator><creator>Magro, Cynthia</creator><creator>Shoushtari, Alexander</creator><creator>Rudin, Charles</creator><creator>Rotemberg, Veronica</creator><creator>Rossi, Anthony</creator><creator>Lezcano, Cecilia</creator><creator>Carrino, John</creator><creator>Fernandez, David</creator><creator>Postow, Michael A</creator><creator>Apollo, Arlyn</creator><creator>Lacouture, Mario E</creator><creator>Bass, Anne R</creator><general>John Wiley &amp; Sons, Inc</general><scope>NPM</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8619-8588</orcidid><orcidid>https://orcid.org/0000-0002-8065-4412</orcidid><orcidid>https://orcid.org/0000-0001-5204-3465</orcidid><orcidid>https://orcid.org/0000-0002-3367-7961</orcidid><orcidid>https://orcid.org/0000-0003-0639-2677</orcidid><orcidid>https://orcid.org/0000-0002-3225-8351</orcidid><orcidid>https://orcid.org/0000-0003-3472-2469</orcidid><orcidid>https://orcid.org/0000-0002-4818-3710</orcidid></search><sort><creationdate>20200201</creationdate><title>Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature</title><author>Chan, Karmela Kim ; Magro, Cynthia ; Shoushtari, Alexander ; Rudin, Charles ; Rotemberg, Veronica ; Rossi, Anthony ; Lezcano, Cecilia ; Carrino, John ; Fernandez, David ; Postow, Michael A ; Apollo, Arlyn ; Lacouture, Mario E ; Bass, Anne R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p163t-ad60bdd65494e2bbda494b92e9dc01dbb36883c47baf47bc790fc8db2b887fe43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Immuno‐Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, Karmela Kim</creatorcontrib><creatorcontrib>Magro, Cynthia</creatorcontrib><creatorcontrib>Shoushtari, Alexander</creatorcontrib><creatorcontrib>Rudin, Charles</creatorcontrib><creatorcontrib>Rotemberg, Veronica</creatorcontrib><creatorcontrib>Rossi, Anthony</creatorcontrib><creatorcontrib>Lezcano, Cecilia</creatorcontrib><creatorcontrib>Carrino, John</creatorcontrib><creatorcontrib>Fernandez, David</creatorcontrib><creatorcontrib>Postow, Michael A</creatorcontrib><creatorcontrib>Apollo, Arlyn</creatorcontrib><creatorcontrib>Lacouture, Mario E</creatorcontrib><creatorcontrib>Bass, Anne R</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, Karmela Kim</au><au>Magro, Cynthia</au><au>Shoushtari, Alexander</au><au>Rudin, Charles</au><au>Rotemberg, Veronica</au><au>Rossi, Anthony</au><au>Lezcano, Cecilia</au><au>Carrino, John</au><au>Fernandez, David</au><au>Postow, Michael A</au><au>Apollo, Arlyn</au><au>Lacouture, Mario E</au><au>Bass, Anne R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>25</volume><issue>2</issue><spage>140</spage><epage>149</epage><pages>140-149</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. The condition is rare, yet at our institutions we have seen four cases in the past 3 years. We describe our 4 cases and review 11 other cases reported in the literature. We present four cases of eosinophilic fasciitis following treatment with programmed cell death protein 1 or programmed cell death-ligand 1 blockade. All patients had extremity involvement with characteristic skin changes ranging from peripheral edema to induration, tightening, and joint limitation. The patients had varying degrees of peripheral eosinophilia. In two of our patients, the diagnosis was made by full-thickness skin biopsy showing lymphocytic infiltration of the subcutaneous fascia, with CD4+ T cells predominating in one case and CD8+ T cells in the other. In the other two cases, the diagnosis was made on the basis of characteristic imaging findings in the context of clinical features consistent with the diagnosis. All four patients were treated with glucocorticoids with varying degrees of success; immunotherapy had to be discontinued in all four. Patients with advanced melanoma who experienced this adverse effect had either a partial response or a complete response to therapy. Eosinophilic fasciitis can occur as a result of checkpoint inhibitor therapy. Although a tissue diagnosis is the gold standard, imaging studies may facilitate the diagnosis in the presence of consistent clinical features, but a degree of suspicion is key to recognizing the condition early. Therapy requires a collaborative approach by oncology, rheumatology, and dermatology; physical therapy is an important adjunct in treatment. For advanced melanoma, it may be a good prognostic indicator. It is important for clinicians to recognize that eosinophilic fasciitis is a potential immune-related adverse event (irAE) as a consequence of immune checkpoint inhibitor therapy. The presentation is quite stereotypical; the diagnosis can be made by imaging in the absence of a full-thickness skin biopsy. Early intervention is important to limit morbidity. This irAE may be a good prognostic sign among patients with melanoma.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32043775</pmid><doi>10.1634/theoncologist.2019-0508</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8619-8588</orcidid><orcidid>https://orcid.org/0000-0002-8065-4412</orcidid><orcidid>https://orcid.org/0000-0001-5204-3465</orcidid><orcidid>https://orcid.org/0000-0002-3367-7961</orcidid><orcidid>https://orcid.org/0000-0003-0639-2677</orcidid><orcidid>https://orcid.org/0000-0002-3225-8351</orcidid><orcidid>https://orcid.org/0000-0003-3472-2469</orcidid><orcidid>https://orcid.org/0000-0002-4818-3710</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1083-7159
ispartof The oncologist (Dayton, Ohio), 2020-02, Vol.25 (2), p.140-149
issn 1083-7159
1549-490X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7011633
source Open Access: PubMed Central; Oxford University Press Open Access; EZB Electronic Journals Library
subjects Immuno‐Oncology
title Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A40%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eosinophilic%20Fasciitis%20Following%20Checkpoint%20Inhibitor%20Therapy:%20Four%20Cases%20and%20a%20Review%20of%20Literature&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Chan,%20Karmela%20Kim&rft.date=2020-02-01&rft.volume=25&rft.issue=2&rft.spage=140&rft.epage=149&rft.pages=140-149&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2019-0508&rft_dat=%3Cpubmed%3E32043775%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p163t-ad60bdd65494e2bbda494b92e9dc01dbb36883c47baf47bc790fc8db2b887fe43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32043775&rfr_iscdi=true